ArticleMolecular neurobiology2026
Sex-dependent Hippocampal Astrocytic Signaling and Synaptic Alterations Associated With Behavioral Impairments in Intracerebroventricular Streptozotocin-treated Rats.
Article in Molecular neurobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Sporadic Alzheimer's disease (AD) disproportionately affects women, yet sex differences in disease mechanisms remain incompletely understood, raising the question of whether preclinical models such as the intracerebroventricular (ICV) streptozotocin (STZ) model adequately capture sex-dependent differences. We examined whether STZ-induced alterations are similarly expressed in males and females and whether ovarian hormones modulate vulnerability to STZ. Three-month-old Sprague-Dawley male, intact female, and ovariectomized (OVX) female rats received ICV artificial cerebrospinal fluid or STZ (3 mg/kg). Behavioral testing was conducted 14-24 days post-injection, followed by hippocampal analyses. STZ increased depressive-like behavior and reduced species-typical burying behavior overall (both p < 0.0001), whereas recognition memory performance did not differ significantly between groups. Spatial memory was more impaired in STZ-treated males, which showed increased Barnes maze latency (p = 0.0027) and fewer head entries into the goal sector (p = 0.0315) than male controls. STZ also reduced PSA-NCAM-positive cells across groups (p < 0.0001) and increased GFAP expression in CA3 (p = 0.0401). Nuclear STAT3 activation increased in STZ-treated males in CA3 (p = 0.004), CA1 (p = 0.0323), and dentate gyrus (p = 0.0058), while synaptic density in the CA3 stratum lucidum was reduced in STZ-treated males (p = 0.0208). Ovarian hormone depletion did not increase female susceptibility to STZ for these key sex-dependent outcomes. Overall, males showed greater vulnerability to STZ-induced spatial memory deficits, astrocytic JAK/STAT3 activation, and synaptic loss, whereas both intact and ovariectomized females displayed an attenuated early phenotype. These findings indicate that the STZ-induced AD-like phenotype is not equivalently expressed across sexes and underscore sex as a critical variable in the translational interpretation of this model.
Indexed as
Identifiers
42744995What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.